Thursday 16 October, 2025
Objectives: Chronic lymphocytic leukaemia (CLL) is a type of leukaemia that affects developing B-lymphocytes, with a diverse biological and clinical behavior1. …
Read morePoster: Drug/Disease Modelling - Oncology
Population PK modelling of camizestrant, a next-generation oral selective estrogen receptor degrader, as monotherapy and in combination with palbociclib in ER+/HER2- advanced breast cancer
Thursday 16 October, 2025
Introduction/Objectives: Camizestrant (AZD9833) is a next-generation oral selective estrogen receptor (ER) degrader and pure ER antagonist currently under Phase 3…
Read moreElucidating the effect of platelet binding on vincristine distribution by a physiologically based pharmacokinetic (PBPK) approach
Thursday 16 October, 2025
Objectives: A poor correlation between vincristine dose and plasma exposure has been observed, indicating nonlinear drug pharmacokinetics (PK) [1]. Several…
Read moreCeralasertib-induced haematological toxicity modelling to support monotherapy Recommended Phase 2 Dose determination
Thursday 16 October, 2025
Objectives: Ceralasertib (AZD6738) is an inhibitor of the ATR protein kinase, the apical kinase in the replication stress response DNA-damage induced…
Read moreTranslational modelling of tumor growth inhibition and treatment resistance for a molecule targeting apoptosis pathway
Thursday 16 October, 2025
Objectives: A small molecule (drug S) is currently under development for treatment of cancer patients, targeting the regulation of apoptosis….
Read moreEvaluation and Optimization of Model-based Translations in Oncology – From Xenografts to RECIST
Thursday 16 October, 2025
Objectives: Evaluate currently used translational methods in oncology using preclinical (xenograft data) and clinical data (response rate based on RECIST…
Read moreModel-based Prediction of Progression-Free Survival for Combination Therapies in Oncology
Thursday 16 October, 2025
Objectives: Extend a joint modeling approach for predicting progression-free survival (PFS) for monotherapies [1] to combination therapies. Test the model’s…
Read moreInfluence of body composition on the pharmacokinetics of monoclonal antibodies : example of cetuximab and bevacizumab
Thursday 16 October, 2025
Introduction : The exposure-response relationship of monoclonal antibodies (mAbs) in oncology is complex and may be blurred by several confounding factors….
Read moreTarget-mediated pharmacokinetics of cetuximab: target occupancy influences progression-free survival
Thursday 16 October, 2025
Introduction: Cetuximab (ERBITUX®), an anti-EGFR monoclonal IgG1 antibody, has been approved for the treatment of metastatic colorectal cancer (mCRC). The…
Read moreRevealing the complexity of monoclonal antibodies exposure-response relationship in metastatic colorectal cancer patients while mitigating confounding factors
Thursday 16 October, 2025
Introduction: Monoclonal antibodies (mAbs) exposure-response relationship in oncology is complex and associated with an important inter-individual variability [1–3]. Several confounding…
Read more